EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma

Gang Xiao, Lifeng Li, Guilong Tanzhu, Zhiyuan Liu, Xuan Gao, Xin Wan, Desheng Xiao, Liu Chen, Xuefeng Xia, Rongrong Zhou iD

Journal for ImmunoTherapy of Cancer · 2023-03 · 11 (3) · e006243

DOI: 10.1136/jitc-2022-006243 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 03.03.2023. Verfasst von Gang Xiao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Xiangya Hospital Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Brain Neoplasms, Lung Neoplasms. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Multidisciplinary Cooperative Diagnosis and Treatment Capacity Building Project for Major Diseases of Chin, Advanced Lung Cancer Research Fund for targeted therapy in China, Beijing Xisike Clinical Oncology and Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Previous studies found that lung adenocarcinomas (LUAD) with EGFR-positive and ALK-positive were less responsive to immunotherapy, which may be associated with a suppressive tumor immune microenvironment (TIME). Given the discordance in the TIME between primary lung cancer and brain metastasis, it is urgent to explore the TIME in patients with EGFR/ALK-positive LUAD with brain metastases (BMs).

Methods

The transcriptome feature of formalin-fixed and paraffin-embedded samples of BMs and paired primary LUAD from 70 patients with LUAD BMs was illustrated by RNA-sequencing. Six of them were available for paired sample analysis. Then, after excluding 3 co-occurring patients, we divided 67 BMs patients into 41 EGFR/ALK-positive and 26 EGFR/ALK-negative patients. The differences in immune profiling between the two groups were analyzed from three dimensions: TIME, T-cell receptor repertoire, and immunohistochemistry. Finally, the survival data of 55 patients were collected.

Results

Compared with primary LUAD, BMs present an immunosuppressed TIME, manifested as: inhibition of immune-related pathways; low expression of immune checkpoint; decreased infiltration of CD8+T cells and cytotoxic lymphocyte; increased proportion of suppressive M2 macrophages. In different subgroups based on EGFR/ALK gene variation status, both EGFR-positive and ALK-positive tumors present a relatively immunosuppressive microenvironment, but the heterogeneity of tumor microenvironment may undergo different mechanisms. EGFR-positive BMs showed decreased CD8+T cells and increased regulatory T cells (Treg) cells, while ALK-positive BMs showed decreased CD8+T cells and increased M2 macrophages. Moreover, in the TCGA-LUAD cohort, EGFR-positive tumors showed reduced CD8+T cell infiltrations (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungBrain NeoplasmsLung NeoplasmsHumansErbB ReceptorsImmunosuppressive AgentsReceptor Protein-Tyrosine KinasesTumor Microenvironment

Stichwörter der Autor:innen

Brain NeoplasmsImmunity, CellularLung NeoplasmsTumor Microenvironment

Substanzen

EGFR protein, humanErbB ReceptorsImmunosuppressive AgentsReceptor Protein-Tyrosine Kinases

Autor:innen und Institutionen

  • Department of Radiation Oncology, Xiangya Hospital Central South University, Changsha, Hunan, China.
  • Geneplus-Beijing, Beijing, China.
  • Institute of Microbiology, Chinese Academy of Sciences, State Key Laboratory of Microbial Resources, Beijing, China.
  • GenePlus-Shenzhen Clinical Laboratory, Shenzhen, China.
  • Department of Neurosurgery, Xiangya Hospital Central South University, Changsha, Hunan, China.
  • Department of Pathology, Xiangya Hospital Central South University, Changsha, Hunan, China.

ORCID-Profile: Rongrong Zhou

Förderung

  • National Multidisciplinary Cooperative Diagnosis and Treatment Capacity Building Project for Major Diseases of Chin
  • Advanced Lung Cancer Research Fund for targeted therapy in China
  • Beijing Xisike Clinical Oncology and Research Foundation

Zitieren

APA

Xiao, G., Li, L., Tanzhu, G., Liu, Z., Gao, X., Wan, X., Xiao, D., Chen, L., Xia, X., & Zhou, R. (2023). Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma. Journal for ImmunoTherapy of Cancer, 11(3), e006243. https://doi.org/10.1136/jitc-2022-006243

Vancouver

Xiao G, Li L, Tanzhu G, Liu Z, Gao X, Wan X, et al. Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma. Journal for ImmunoTherapy of Cancer. 2023;11(3):e006243. doi:10.1136/jitc-2022-006243

BibTeX
@article{Xiao2023,
  author = {Xiao, Gang and Li, Lifeng and Tanzhu, Guilong and Liu, Zhiyuan and Gao, Xuan and Wan, Xin and Xiao, Desheng and Chen, Liu and Xia, Xuefeng and Zhou, Rongrong},
  title = {Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  volume = {11},
  number = {3},
  pages = {e006243},
  doi = {10.1136/jitc-2022-006243}
}
Kostenlos starten →